(Q43849865)

27 November 2017

title

Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (English)

1 reference

27 November 2017

1 reference

2

1 reference

27 November 2017

author name string

Nuria Arroyo De Prada

1

1 reference

27 November 2017

Eva-Kathrin Sinner

3

1 reference

27 November 2017

Bernd Muehlenweg

4

1 reference

27 November 2017

Jens Twellmeyer

5

1 reference

27 November 2017

Stefan Sperl

6

1 reference

27 November 2017

Olaf G Wilhelm

7

1 reference

27 November 2017

Manfred Schmitt

8

1 reference

27 November 2017

Viktor Magdolen

9

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

269

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

184-192

1 reference

The urokinase-type plasminogen activator system in cancer metastasis: a review

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

The plasminogen activation system in tumor growth, invasion, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Structural basis of latency in plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Regulation of cell adhesion by PAI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI‐1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0014-2956.2002.02639.X

10.1046/J.0014-2956.2002.02639.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference